Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic
Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a fixed regimen and evaluate the treatment response of three types of choroidal neovascular membrane (CNV)—occult (Type 1), classic (Type 2), and...
Saved in:
Main Authors: | Jan Nemcansky, Alexandr Stepanov, Michal Koubek, Miroslav Veith, Yun Min Klimesova, Jan Studnicka |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2019/2635689 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01) -
Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
by: David R. Griffin, et al.
Published: (2014-01-01) -
Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
by: Juliana Wons, et al.
Published: (2017-01-01) -
The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration
by: N.S. Zhayvoronok, et al.
Published: (2022-11-01) -
The first experience with brolucizumab for neovascular age-related macular degeneration
by: A.N. Kulikov, et al.
Published: (2022-05-01)